Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Nov;91(11):1471-2.
doi: 10.1136/hrt.2004.051425.

Prediction of beneficial effect of beta blocker treatment in severe ischaemic cardiomyopathy: assessment of global left ventricular ejection fraction using dobutamine stress cardiovascular magnetic resonance

T A M Kaandorp, H J Lamb, J J Bax, E Boersma, E P Viergever, E E van der Wall, A de Roos

Prediction of beneficial effect of beta blocker treatment in severe ischaemic cardiomyopathy: assessment of global left ventricular ejection fraction using dobutamine stress cardiovascular magnetic resonance

T A M Kaandorp et al. Heart. 2005 Nov.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
(A) Comparison of responders and non-responders to carvedilol treatment, showing the effect of low dose dobutamine stress before starting treatment. Note the increase in LVEF during dobutamine infusion at baseline in responders (p < 0.01), as compared to the modest improvement in non-responders (p > 0.05). (B) Linear regression analysis of the difference in LVEF during dobutamine stress versus resting LVEF, both before treatment, and the difference in LVEF at follow up versus resting LVEF before treatment.
See this image and copyright information in PMC

References

    1. Lechat P, Escolano S, Golmard JL, et al. Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the cardiac insufficiency bisoprolol study (CIBIS). Circulation 1997;96:2197–205. - PubMed
    1. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. carvedilol heart failure study group. N Engl J Med 1996;334:1349–55. - PubMed
    1. Bellenger NG, Davies LC, Francis JM, et al. Reduction in sample size for studies of remodeling in heart failure by the use of cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2000;2:271–8. - PubMed
    1. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol European trial (COMET): randomised controlled trial. Lancet 2003;362:7–13. - PubMed
    1. Bax JJ, Visser FC, Poldermans D, et al. Relationship between preoperative viability and postoperative improvement in LVEF and heart failure symptoms. J Nucl Med 2001;42:79–86. - PubMed

Publication types